 Amid ongoing efforts to combat the novel coronavirus, one local company is taking strides toward solving another major and related health care challenge. Gaithersburgs Adaptive Phage Therapeutics Inc. just got the green light to kick off human clinical trials for PhageBank, APTs collection of viruses, or phages, that target specific pathogens and kill antibiotic-resistant bacteria, or superbugs. The Food and Drug Administrations approval of the companys Investigational New Drug application means it can enroll patients in its study in the second quarter of this year. 